{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:25:16Z","timestamp":1751516716559},"reference-count":49,"publisher":"Impact Journals, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"DOI":"10.18632\/aging.205782","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:53:15Z","timestamp":1714575195000},"source":"Crossref","is-referenced-by-count":1,"title":["The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma"],"prefix":"10.18632","author":[{"given":"Xudong","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjiong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhehao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.eururo.2019.07.032","article-title":"Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.","volume":"7","author":"Mamtani","year":"2019","journal-title":"Eur Urol"},{"key":"2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1200\/JCO.2017.72.8444","article-title":"Immune Checkpoint Blockade in Metastatic Urothelial Cancer.","volume":"3","author":"Balar","year":"2017","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1634\/theoncologist.2019-0039","article-title":"Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice.","volume":"2","author":"Mamtani","year":"2019","journal-title":"Oncologist"},{"key":"4","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.","volume":"11","author":"Kinoshita","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.1038\/s41388-021-02019-6","article-title":"CD8T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.","volume":"4","author":"Cao","year":"2021","journal-title":"Oncogene"},{"key":"6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020.","volume":"7","author":"Galsky","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"7","doi-asserted-by":"publisher","first-page":"612337","DOI":"10.3389\/fonc.2020.612337","article-title":"The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy.","volume":"1","author":"Dash","year":"2021","journal-title":"Front Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12916-021-02148-5","article-title":"mA regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer.","volume":"1","author":"Xue","year":"2021","journal-title":"BMC Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12943-022-01558-0","article-title":"Targeting the RNA mA modification for cancer immunotherapy.","volume":"2","author":"Yu","year":"2022","journal-title":"Mol Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-022-01704-8","article-title":"mA methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion.","volume":"2","author":"Xiao","year":"2023","journal-title":"Mol Cancer"},{"key":"11","doi-asserted-by":"publisher","first-page":"e113126","DOI":"10.15252\/embj.2022113126","article-title":"YTHDF2\/mA\/NF-\u03baB axis controls anti-tumor immunity by regulating intratumoral Tregs.","volume":"4","author":"He","year":"2023","journal-title":"EMBO J"},{"key":"12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s10753-023-01841-2","article-title":"m6A Regulator-mediated RNA Methylation Modulates Immune Microenvironment of Hepatitis B Virus-related Acute Liver Failure.","volume":"4","author":"You","year":"2023","journal-title":"Inflammation"},{"key":"13","doi-asserted-by":"publisher","first-page":"101683","DOI":"10.1016\/j.tranon.2023.101683","article-title":"RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8T cell infiltration in colorectal cancer.","volume":"3","author":"Yang","year":"2023","journal-title":"Transl Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s40425-019-0619-8","article-title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.","volume":"7","author":"Koti","year":"2019","journal-title":"J Immunother Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1200\/JCO.22.02144","article-title":"Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.","volume":"4","author":"Greenbaum","year":"2023","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"719863","DOI":"10.3389\/fonc.2021.719863","article-title":"Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer.","volume":"1","author":"Zuo","year":"2021","journal-title":"Front Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.urolonc.2010.02.011","article-title":"Statistical consideration for clinical biomarker research in bladder cancer.","volume":"2","author":"Malats","year":"2010","journal-title":"Urol Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12026-014-8516-1","article-title":"ImmPort: disseminating data to the public for the future of immunology.","volume":"5","author":"Guimaraes","year":"2014","journal-title":"Immunol Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/sam.10103","article-title":"Random survival forests for high-dimensional data.","volume":"4","author":"Minn","year":"2011","journal-title":"Stat Anal Data Min"},{"key":"20","doi-asserted-by":"publisher","first-page":"D269","DOI":"10.1093\/nar\/gkac945","article-title":"RM2Target: a comprehensive database for targets of writers, erasers and readers of RNA modifications.","volume":"5","author":"Zuo","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.","volume":"38","author":"Dreicer","year":"2017","journal-title":"Lancet"},{"key":"22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1198\/jasa.2009.tm08622","article-title":"High-dimensional variable selection for survival data.","volume":"10","author":"Lauer","year":"2010","journal-title":"J Am Stat Assoc"},{"key":"23","first-page":"25","article-title":"Random survival forests for R.","author":"Kogalur","year":"2007","journal-title":"R news 7"},{"key":"24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","article-title":"EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data.","volume":"212","author":"Gfeller","year":"2020","journal-title":"Methods Mol Biol"},{"key":"25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling Tumor Infiltrating Immune Cells with CIBERSORT.","volume":"171","author":"Alizadeh","year":"2018","journal-title":"Methods Mol Biol"},{"key":"26","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Stemke-Hale","year":"2013","journal-title":"Nat Commun"},{"key":"27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.","volume":"3","author":"Becker","year":"2013","journal-title":"Immunity"},{"key":"28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/d41573-019-00179-5","article-title":"Chemical inhibitors make their RNA epigenetic mark.","volume":"1","author":"Cully","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"29","doi-asserted-by":"publisher","first-page":"108950","DOI":"10.1016\/j.abb.2021.108950","article-title":"Characterization of the immune cell infiltration landscape in bladder cancer to aid immunotherapy.","volume":"70","author":"Xi","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2017.08.030","article-title":"Roles of RNA methylation by means of N-methyladenosine (mA) in human cancers.","volume":"40","author":"Yin","year":"2017","journal-title":"Cancer Lett"},{"key":"31","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.18632\/aging.202359","article-title":"Dysregulation of USP18\/FTO\/PYCR1 signaling network promotes bladder cancer development and progression.","volume":"1","author":"Gao","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","article-title":"mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.","volume":"3","author":"Chen","year":"2020","journal-title":"Cancer Cell"},{"key":"33","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","article-title":"Role of immunotherapy in bladder cancer.","volume":"2","author":"Aragon-Ching","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1200\/PO.20.00150","article-title":"Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade.","volume":"4","author":"Schoenfeld","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"e91272","DOI":"10.1371\/journal.pone.0091272","article-title":"Increasing consistency of disease biomarker prediction across datasets.","volume":"9","author":"Sealfon","year":"2014","journal-title":"PLoS One"},{"key":"36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12967-022-03711-1","article-title":"m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.","volume":"2","author":"Luo","year":"2022","journal-title":"J Transl Med"},{"key":"37","doi-asserted-by":"publisher","first-page":"1050288","DOI":"10.3389\/fonc.2022.1050288","article-title":"Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival.","volume":"1","author":"Zeng","year":"2022","journal-title":"Front Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"BSR20204456","DOI":"10.1042\/BSR20204456","article-title":"A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.","volume":"4","author":"He","year":"2021","journal-title":"Biosci Rep"},{"key":"39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41590-020-0650-4","article-title":"The RNA modification N-methyladenosine as a novel regulator of the immune system.","volume":"2","author":"Stern-Ginossar","year":"2020","journal-title":"Nat Immunol"},{"key":"40","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","article-title":"The Critical Role of RNA mA Methylation in Cancer.","volume":"7","author":"Liu","year":"2019","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The Roles of CD8T Cell Subsets in Antitumor Immunity.","volume":"3","author":"Ohashi","year":"2020","journal-title":"Trends Cell Biol"},{"key":"42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8T cells in cancer and cancer immunotherapy.","volume":"12","author":"G\u00f6genur","year":"2021","journal-title":"Br J Cancer"},{"key":"43","first-page":"2005","article-title":"Tumour MHC class I downregulation and immunotherapy (Review).","volume":"1","author":"Buben\u00edk","year":"2003","journal-title":"Oncol Rep"},{"key":"44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy.","volume":"3","author":"van Hall","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"HLA class I antigen abnormalities and immune escape by malignant cells.","volume":"1","author":"Ferrone","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4T cell-induced inflammatory cell death controls immune-evasive tumours.","volume":"61","author":"Antoranz","year":"2023","journal-title":"Nature"},{"key":"47","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses.","volume":"18","author":"Eisenbarth","year":"2021","journal-title":"Cell"},{"key":"48","doi-asserted-by":"publisher","first-page":"eabg0470","DOI":"10.1126\/sciadv.abg0470","article-title":"mA demethylase ALKBH5 controls CD4T cell pathogenicity and promotes autoimmunity.","volume":"7","author":"Li","year":"2021","journal-title":"Sci Adv"},{"key":"49","doi-asserted-by":"publisher","first-page":"107819","DOI":"10.1016\/j.celrep.2020.107819","article-title":"Control of Early B Cell Development by the RNA N-Methyladenosine Methylation.","volume":"3","author":"Clark","year":"2020","journal-title":"Cell Rep"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:53:20Z","timestamp":1714575200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":49,"alternative-id":["205782"],"URL":"https:\/\/doi.org\/10.18632\/aging.205782","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}